STEREOSELECTIVE INHIBITION OF MUSCARINIC RECEPTOR SUBTYPES BY THE ENANTIOMERS OF HEXAHYDRO-DIFENIDOL AND ACETYLENIC ANALOGS

被引:26
作者
FEIFEL, R
WAGNERRODER, M
STROHMANN, C
TACKE, R
WAELBROECK, M
CHRISTOPHE, J
MUTSCHLER, E
LAMBRECHT, G
机构
[1] UNIV FRANKFURT, DEPT PHARMACOL, THEODOR STERN KAI 7, GEBAUDE 75A, W-6000 FRANKFURT, GERMANY
[2] UNIV KARLSRUHE, INST INORGAN CHEM, W-7500 KARLSRUHE, GERMANY
[3] FREE UNIV BRUSSELS, SCH MED, DEPT BIOCHEM & NUTR, B-1000 BRUSSELS, BELGIUM
关键词
D O I
10.1111/j.1476-5381.1990.tb12949.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The affinities of the (R)- and (S)-enantiomers of hexahydro-difenidol (1) and its acetylenic analogues hexbutinol (2), hexbutinol methiodide (3) and p-fluoro-hexbutinol (4) (stereochemical purity > 99.8%) for muscarinic receptors in rabbit vas deferens (M1), guinea-pig atria (M2) and guinea-pig ileum (M3) were measured by dose-ratio experiments. The (R)-enantiomers consistently showed higher affinities than the (S)-isomers. The stereoselectivity ratios [(R)/(S)] were greatest with the enantiomers of 1 (vas deferens: 550; ileum: 191; atria: 17) and least with those of the p-Fluoro-analogue 4 (vas deferens: 34; ileum: 8.5; atria: 1.7). The enantiomeric potency ratios for compounds 1-4 were highest in rabbit vas deferens, intermediate in guinea-pig ileum and much less in guinea-pig atria. Thus, these ratios may serve as a predictor of muscarinic receptor subtype identity. (S)-p-Fluoro-hexbutinol [S)-4] showed a noval receptor selectivity profile with preference for M3 receptors: M3 > M2 ≥ M1. These results do not conform to Pfeiffer's rule that activity differences between enantiomers are greater with more potent compounds.
引用
收藏
页码:455 / 460
页数:6
相关论文
共 46 条
[21]   MUSCARINIC GANGLIONIC STIMULANTS - CONFORMATIONALLY RESTRAINED ANALOGS RELATED TO [4-[[N-(3-CHLOROPHENYL)CARBAMOYL]OXY]-2-BUTYNYL]TRIMETHYLAMMONIUM CHLORIDE [J].
LAMBRECHT, G ;
MOSER, U ;
MUTSCHLER, E ;
WALTHER, G ;
WESS, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (07) :1309-1311
[22]  
LAMBRECHT G, 1986, INNOVATIVE APPROACHE, P353
[23]  
LAMBRECHT G, 1989, TRENDS MED CHEM 88, P265
[24]   STEREOISOMERISM AND DRUG-ACTION [J].
LEHMANN, PA .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1986, 7 (07) :281-285
[25]   TISSUE DISTRIBUTION OF MESSENGER-RNAS ENCODING MUSCARINIC ACETYLCHOLINE-RECEPTOR SUBTYPES [J].
MAEDA, A ;
KUBO, T ;
MISHINA, M ;
NUMA, S .
FEBS LETTERS, 1988, 239 (02) :339-342
[26]   ANTIMUSCARINIC ACTION OF METHOCTRAMINE, A NEW CARDIOSELECTIVE M-2 MUSCARINIC RECEPTOR ANTAGONIST, ALONE AND IN COMBINATION WITH ATROPINE AND GALLAMINE [J].
MELCHIORRE, C ;
ANGELI, P ;
LAMBRECHT, G ;
MUTSCHLER, E ;
PICCHIO, MT ;
WESS, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 144 (02) :117-124
[27]   MUSCARINIC RECEPTOR DIFFERENTIATION [J].
MITCHELSON, F .
PHARMACOLOGY & THERAPEUTICS, 1988, 37 (03) :357-423
[28]   STRUCTURE-ACTIVITY-RELATIONSHIPS OF NEW ANALOGS OF ARECAIDINE PROPARGYL ESTER AT MUSCARINIC-M1 AND MUSCARINIC-M2 RECEPTOR SUBTYPES [J].
MOSER, U ;
LAMBRECHT, G ;
WAGNER, M ;
WESS, J ;
MUTSCHLER, E .
BRITISH JOURNAL OF PHARMACOLOGY, 1989, 96 (02) :319-324
[29]  
MUTSCHLER E, 1973, ARZNEIMITTELFORSCH, V23, P732
[30]  
MUTSCHLER E, 1984, TRENDS PHARM SCI S, V5, P39